Phase 3 Clinical Trials - Hua Medicine
COVID-19 in China
This year the 80th American Diabetes Association Scientific Sessions was shared with the world as A Virtual Experience. WebsEdge was proud to partner again with ADA to create a virtual version of ADATV. As part of this WebsEdge partnered with Hua Medicine to focus on their COVID-19 research related to diabetes.
When COVID-19 hit China, it soon emerged that people with Diabetes were more adversely affected. Companies like Hua Medicine who are working on a glucose-sensor repair drug for T2D, had to adapt to the conditions. Hua was able to complete Phase 3 Clinical Trials at the height of the pandemic in early March by online patient reporting and web-based supply chain for drug delivery, and hope to unveil the results in the coming year.